NO20062930L - Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779 - Google Patents
Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779Info
- Publication number
- NO20062930L NO20062930L NO20062930A NO20062930A NO20062930L NO 20062930 L NO20062930 L NO 20062930L NO 20062930 A NO20062930 A NO 20062930A NO 20062930 A NO20062930 A NO 20062930A NO 20062930 L NO20062930 L NO 20062930L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical composition
- directly compressible
- oral administration
- compressible pharmaceutical
- directly
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 abstract 1
- CBPNZQVSJQDFBE-HXVVJGEPSA-N ccl-779 Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HXVVJGEPSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53495104P | 2004-01-08 | 2004-01-08 | |
| PCT/US2004/042178 WO2005070393A2 (en) | 2004-01-08 | 2004-12-14 | Directly compressible pharmaceutical composition of the rapamycin ester cci-779 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20062930L true NO20062930L (no) | 2006-10-02 |
Family
ID=34806893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20062930A NO20062930L (no) | 2004-01-08 | 2006-06-22 | Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20050152983A1 (da) |
| EP (1) | EP1701698B1 (da) |
| JP (1) | JP2007517879A (da) |
| KR (1) | KR20060130162A (da) |
| CN (1) | CN1921861A (da) |
| AR (1) | AR047180A1 (da) |
| AT (1) | ATE383859T1 (da) |
| AU (1) | AU2004314213A1 (da) |
| BR (1) | BRPI0418373A (da) |
| CA (1) | CA2552595A1 (da) |
| CR (1) | CR8491A (da) |
| CY (1) | CY1107373T1 (da) |
| DE (1) | DE602004011398T2 (da) |
| DK (1) | DK1701698T3 (da) |
| EC (1) | ECSP066757A (da) |
| ES (1) | ES2298861T3 (da) |
| GT (1) | GT200500003A (da) |
| HN (1) | HN2005000005A (da) |
| IL (1) | IL176519A0 (da) |
| MX (1) | MXPA06007829A (da) |
| NO (1) | NO20062930L (da) |
| PA (1) | PA8621201A1 (da) |
| PE (1) | PE20050683A1 (da) |
| PL (1) | PL1701698T3 (da) |
| PT (1) | PT1701698E (da) |
| RU (1) | RU2006122517A (da) |
| TW (1) | TW200526213A (da) |
| UA (1) | UA84903C2 (da) |
| WO (1) | WO2005070393A2 (da) |
| ZA (1) | ZA200605631B (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023254A1 (en) | 2003-09-03 | 2005-03-17 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same |
| BRPI0509852A (pt) * | 2004-04-14 | 2007-10-23 | Wyeth Corp | método para a preparação regioespecìfica dos derivados de 42-éster de rapamicina, preparação regioespecìfica do 42-éster de rapamicina, composição, produto, e, kit farmacêutico |
| BRPI0510277A (pt) * | 2004-04-27 | 2007-10-30 | Wyeth Corp | método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit |
| RU2007127499A (ru) * | 2005-02-15 | 2009-03-27 | Вайет (Us) | Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме |
| EA015922B1 (ru) | 2005-11-14 | 2011-12-30 | Ариад Фармасьютикалз, Инк. | ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ |
| WO2008003050A2 (en) * | 2006-06-28 | 2008-01-03 | Emisphere Technologies, Inc. | Gallium nitrate formulations |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| JP2013527223A (ja) | 2010-06-02 | 2013-06-27 | フレゼニウス・カビ・オンコロジー・リミテッド | ラパマイシンエステルの安定な医薬組成物 |
| MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| MX387669B (es) | 2012-06-04 | 2025-03-18 | Pharmacyclics Llc | Formas cristalinas de un inhibidor de tirosina quinasa de bruton. |
| BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| CN104721158B (zh) * | 2013-12-24 | 2018-01-30 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| WO2017038925A1 (ja) * | 2015-09-03 | 2017-03-09 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| WO2017129772A1 (en) | 2016-01-29 | 2017-08-03 | Xellia Phamaceuticals Aps | Stable pharmaceutical compositions of temsirolimus |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5928668A (en) * | 1993-12-21 | 1999-07-27 | Applied Analytical Industries, Inc. | Method for dry blend compression of medicaments |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| RO120603B1 (ro) * | 1996-08-22 | 2006-05-30 | Research Triangle Pharmaceuticals Ltd. | Compoziţie conţinând microparticule de substanţe insolubile în apă şi procedeu de preparare |
| US5989591A (en) * | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5985325A (en) * | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| US20040077677A1 (en) * | 2002-09-17 | 2004-04-22 | Wyeth | Oral formulations |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| RU2345772C2 (ru) * | 2003-07-25 | 2009-02-10 | Уайт | Лиофилизированные композиции cci-779 |
| DK1658295T3 (da) * | 2003-08-07 | 2007-09-24 | Wyeth Corp | Regioselektiv syntese af CCI-779 |
| WO2005023254A1 (en) * | 2003-09-03 | 2005-03-17 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same |
| US20060142422A1 (en) * | 2004-12-07 | 2006-06-29 | Toshikazu Kobayashi | Hydrolysis resistant polyester compositions and articles made therefrom |
| RU2007127499A (ru) * | 2005-02-15 | 2009-03-27 | Вайет (Us) | Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме |
-
2004
- 2004-12-14 BR BRPI0418373-8A patent/BRPI0418373A/pt not_active IP Right Cessation
- 2004-12-14 DK DK04814371T patent/DK1701698T3/da active
- 2004-12-14 EP EP04814371A patent/EP1701698B1/en not_active Expired - Lifetime
- 2004-12-14 PT PT04814371T patent/PT1701698E/pt unknown
- 2004-12-14 PL PL04814371T patent/PL1701698T3/pl unknown
- 2004-12-14 AT AT04814371T patent/ATE383859T1/de not_active IP Right Cessation
- 2004-12-14 RU RU2006122517/15A patent/RU2006122517A/ru not_active Application Discontinuation
- 2004-12-14 MX MXPA06007829A patent/MXPA06007829A/es active IP Right Grant
- 2004-12-14 DE DE602004011398T patent/DE602004011398T2/de not_active Expired - Lifetime
- 2004-12-14 KR KR1020067015655A patent/KR20060130162A/ko not_active Ceased
- 2004-12-14 CA CA002552595A patent/CA2552595A1/en not_active Abandoned
- 2004-12-14 ES ES04814371T patent/ES2298861T3/es not_active Expired - Lifetime
- 2004-12-14 WO PCT/US2004/042178 patent/WO2005070393A2/en not_active Ceased
- 2004-12-14 CN CNA2004800399872A patent/CN1921861A/zh active Pending
- 2004-12-14 JP JP2006549291A patent/JP2007517879A/ja not_active Withdrawn
- 2004-12-14 UA UAA200608870A patent/UA84903C2/ru unknown
- 2004-12-14 AU AU2004314213A patent/AU2004314213A1/en not_active Abandoned
- 2004-12-27 TW TW093140750A patent/TW200526213A/zh unknown
-
2005
- 2005-01-04 AR ARP050100016A patent/AR047180A1/es not_active Application Discontinuation
- 2005-01-05 GT GT200500003A patent/GT200500003A/es unknown
- 2005-01-06 US US11/030,685 patent/US20050152983A1/en not_active Abandoned
- 2005-01-06 PE PE2005000043A patent/PE20050683A1/es not_active Application Discontinuation
- 2005-01-06 HN HN2005000005A patent/HN2005000005A/es unknown
- 2005-01-07 PA PA20058621201A patent/PA8621201A1/es unknown
-
2006
- 2006-06-22 IL IL176519A patent/IL176519A0/en unknown
- 2006-06-22 NO NO20062930A patent/NO20062930L/no not_active Application Discontinuation
- 2006-06-28 CR CR8491A patent/CR8491A/es not_active Application Discontinuation
- 2006-07-07 ZA ZA200605631A patent/ZA200605631B/xx unknown
- 2006-08-08 EC EC2006006757A patent/ECSP066757A/es unknown
-
2008
- 2008-03-31 CY CY20081100359T patent/CY1107373T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004011398D1 (de) | 2008-03-06 |
| MXPA06007829A (es) | 2006-09-01 |
| DK1701698T3 (da) | 2008-05-05 |
| AR047180A1 (es) | 2006-01-11 |
| CR8491A (es) | 2008-08-21 |
| TW200526213A (en) | 2005-08-16 |
| ATE383859T1 (de) | 2008-02-15 |
| WO2005070393A3 (en) | 2006-09-28 |
| JP2007517879A (ja) | 2007-07-05 |
| ES2298861T3 (es) | 2008-05-16 |
| GT200500003A (es) | 2005-08-18 |
| HN2005000005A (es) | 2009-04-17 |
| PA8621201A1 (es) | 2005-12-23 |
| ZA200605631B (en) | 2010-01-27 |
| CA2552595A1 (en) | 2005-08-04 |
| IL176519A0 (en) | 2006-10-05 |
| CN1921861A (zh) | 2007-02-28 |
| DE602004011398T2 (de) | 2009-01-15 |
| RU2006122517A (ru) | 2008-02-20 |
| BRPI0418373A (pt) | 2007-05-22 |
| WO2005070393A2 (en) | 2005-08-04 |
| UA84903C2 (ru) | 2008-12-10 |
| PL1701698T3 (pl) | 2008-03-31 |
| US20050152983A1 (en) | 2005-07-14 |
| EP1701698A2 (en) | 2006-09-20 |
| PE20050683A1 (es) | 2005-11-04 |
| EP1701698B1 (en) | 2008-01-16 |
| AU2004314213A1 (en) | 2005-08-04 |
| CY1107373T1 (el) | 2012-12-19 |
| ECSP066757A (es) | 2006-11-16 |
| PT1701698E (pt) | 2008-03-27 |
| KR20060130162A (ko) | 2006-12-18 |
| HK1090308A1 (en) | 2006-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20062930L (no) | Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779 | |
| ES2729679T3 (es) | Derivados de morfinano para el tratamiento de la sobredosis de fármacos | |
| NO20073786L (no) | Oralt biotilgjengelige CCI-779-formuleringer | |
| BRPI0707235B8 (pt) | formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual | |
| DE60003837D1 (de) | Tetrapeptid, das die funktionelle aktivität von neuronen stimuliert, dieses enthaltendes pharmakologisches mittel und seine verwendung | |
| CY1109962T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας | |
| DK1725233T3 (da) | Farmaceutisk sammensætning omfattende SNS-595 og anvendelse deraf | |
| AR063782A1 (es) | Parche y metodo transdermico para emesis | |
| MX2009010268A (es) | Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. | |
| Hung et al. | Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block | |
| ATE268174T1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| Zheng et al. | Effect of FK‐506 (tacrolimus) therapy on bone healing of titanium implants: a histometric and biomechanical study in mice | |
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| NO20065152L (no) | Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav | |
| ATE283036T1 (de) | Pharmazeutische zusammensetzung mit gesteuerter freigabe enthaltend midodrin und/oder desglymidodrin | |
| GEP201606538B (en) | Preoperative treatment of post operative pain | |
| RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
| ATE513845T1 (de) | Peptidsubstanz mit immunogeroprotektiver wirkung, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung | |
| CA2425445A1 (en) | Tetrapeptide stimulating functional activity of hepatocytes, pharmacological substance on its basis and the method of its application | |
| BRPI0405520A (pt) | novas drogas derivadas do diclofenaco contendo heterociclos doadores de no, composição e método de tratamento de inflamação | |
| Malacco et al. | Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: a randomized, open-label, crossover study | |
| RU2531941C1 (ru) | Способ профилактики и лечения инфекционных процессов при хирургических стоматологических вмешательствах | |
| UA40736U (en) | METHOD FOR TREATMENT OF VERTEBROGENIUOS radiculopathy | |
| SASAKI et al. | Effusion level of exodontia wound after oral administration of cefdinir (CFDN) | |
| UA38381A (uk) | Спосіб комплексної терапії депресивно-параноїдного синдрому у хворих шизофренією |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |